Scharf M B
Sleep Disorders Center, Mercy Hospital, Cincinnati, Ohio 45246.
J Clin Psychiatry. 1993 Jan;54(1):33-8.
Rebound insomnia, a worsening of sleep difficulty beyond baseline levels, can complicate the physician's attempt to use regularly scheduled drug holidays in the management of insomniac patients. Quazepam, a benzodiazepine with a long half-life, has been shown to exhibit carryover effectiveness for the first night or two following withdrawal. This finding suggests a potential utility for an alternate-night drug regimen in which the withdrawal features of the compound serve as a potential benefit.
A randomized, double-blind, three-compartment, parallel-group design of 5 weeks' duration, comparing quazepam 15 mg, triazolam 0.5 mg, and placebo, was conducted in 65 insomniac subjects. This study was a nonpolysomnographic study utilizing sleep questionnaires.
No differences were noted between quazepam and triazolam on treatment nights. Evidence of carryover effectiveness with quazepam and rebound effects with triazolam were noted on off-treatment nights.
The efficiency of alternate-night therapy with quazepam should be rigorously evaluated using polysomnographic determinations.
反弹性失眠,即睡眠困难程度超过基线水平,可能会使医生在为失眠患者安排定期药物假期治疗时变得复杂。夸西泮是一种半衰期较长的苯二氮䓬类药物,已被证明在停药后的头一两个晚上具有持续疗效。这一发现提示了一种交替服药方案的潜在效用,即该化合物的停药特性可能会带来益处。
对65名失眠受试者进行了一项为期5周的随机、双盲、三室、平行组设计研究,比较15毫克夸西泮、0.5毫克三唑仑和安慰剂。本研究是一项使用睡眠问卷的非多导睡眠图研究。
在治疗期间的夜晚,夸西泮和三唑仑之间未观察到差异。在停药期间的夜晚,观察到夸西泮有持续疗效的证据,三唑仑有反弹性效应的证据。
应使用多导睡眠图测定法对夸西泮交替服药疗法的有效性进行严格评估。